Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

Detaylı Bibliyografya
Asıl Yazarlar:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	BioMed Central 2018

Benzer Materyaller

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
Yazar:: Philip Helliwell, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
Yazar:: Helliwell, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
Yazar:: E. Yu. Loginova, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
Yazar:: Tucker, L, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
Yazar:: Miao Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
Yazar:: Lubrano, E, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Current concepts and unmet needs in psoriatic arthritis
Yazar:: Mahmood, F, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Remission in psoriatic arthritis—where are we now?
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
Yazar:: P.S. Helliwell
Baskı/Yayın Bilgisi: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Yazar:: Ennio Lubrano, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Best-practice indicators in Psoriatic disease care
Yazar:: Helliwell, P, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Yazar:: Peter Nash, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Yazar:: Mease, P, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Psoriatic arthritis
Yazar:: FitzGerald, O, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Yazar:: Laura C. Coates, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
Yazar:: Jiao Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
Yazar:: Coates, L, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Yazar:: Soriano, ER, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Psoriatic Arthritis: A Review
Yazar:: Farrouq Mahmood, ve diğerleri
Baskı/Yayın Bilgisi: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Yazar:: Helliwell, PS, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
Yazar:: E. E. Gubar, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Yazar:: Laure Gossec, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
Yazar:: Coates, LC
Baskı/Yayın Bilgisi: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
Yazar:: Vivekanantham, A, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Measuring outcomes in psoriatic arthritis
Yazar:: Ogdie, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Yazar:: Vishal R. Tandon, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
Yazar:: Braun, J, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Yazar:: Philip J. Mease, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Yazar:: Yazji, SM, ve diğerleri
Baskı/Yayın Bilgisi: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Yazar:: Nash, P, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Yazar:: Coates, LC, ve diğerleri
Baskı/Yayın Bilgisi: (2022)